G protein-coupled receptor signaling regulates obesity 1 and modulates adipose tissue macrophage-dependent inflammation 2 . Although crucial regulators of adipose tissue macrophages have been identified [2] [3] [4] [5] [6] , extracellular signals sustaining their proinflammatory phenotype in obesity are unclear. The adaptor protein β-arrestin-2 terminates and mediates signaling of certain G protein-coupled receptors 7, 8 and is important in insulin signaling 9 . PAR2 signals through G protein activation and recruits β-arrestins for scaffolding of cytoskeletal regulators and for suppression of phosphatidyl inositol 3-kinase-dependent Akt phosphorylation 8, 10, 11 . In adipocytes, β-arrestin-2 suppresses AMP-activated protein kinase (AMPK) activation induced by PAR2 G protein-coupled signaling 12 , but it has been unclear whether PAR2 can influence diet-induced obesity (DIO).
Obesity and metabolic disorders induce the expression of prothrombotic molecules (plasminogen activator inhibor-1 (PAI-1) and tissue factor) that are implicated in cardiovascular complications 13, 14 attributed to high levels of circulating tissue factor [15] [16] [17] . However, the functional roles of increased expression of tissue factor in adipose tissues of obese mice 18 are unknown. A range of serine proteases activate PAR2, but coagulation factor VIIa in complex with tissue factor uniquely regulates cell migration though PAR2 activation and phosphorylation-dependent cross-talk of the tissue factor cytoplasmic domain with integrins 19 . Tissue factor-PAR2 signaling also promotes cancer progression and myeloid cell inflammatory signaling leading to fetal loss syndrome 20, 21 , and mice lacking the tissue factor cytoplasmic domain (TF ∆CT mice) phenocopy PAR2 deficiency, demonstrating that the tissue factor cytoplasmic domain is involved in pathological tissue factor-PAR2 signaling. The extracellular pool of tissue factor involved in cell signaling is recognized by a specific antibody to human tissue factor (10H10) 22 that blocks tissue factorVIIa-PAR2 signaling 21, 23 without inhibiting activation of coagulation or downstream coagulation signaling. Here, we used new genetic and pharmacological tools to uncover a signaling pathway in obesity. We found that tissue factor-VIIa-PAR2 signaling of adipocytes crucially regulates weight gain, whereas independently tissue factor-PAR2 signaling of adipose tissue macrophages promotes inflammation leading to insulin resistance.
RESULTS
Tissue factor cytoplasmic domain and PAR2 promote DIO Body weights of aged, syngeneic C57BL/6 male mice on a normal low-fat chow diet ( Supplementary Fig. 1a ) indicated that the tissue factor cytoplasmic domain and PAR2 signaling, but not the thrombin receptor PAR1, contribute to body weight regulation by the tissue factor pathway. Tissue factor activity in plasma and in epididymal visceral adipose tissue (VAD) extracts was upregulated in mice on a high-fat diet (HFD) for 16 weeks (Fig. 1a) concordant with high levels of VAD mRNA of tissue factor and its signaling receptor PAR2 (Fig. 1b) . On a HFD, wild-type (WT) mice gained weight rapidly, whereas a mutant mouse strain lacking the tissue factor cytoplasmic domain (TF ∆CT mice) or PAR2-deficient (F2rl1 −/− ) mice gained less weight, implicating tissue factor and PAR2 in DIO. TF ∆CT ; F2rl1 −/− double-deficient mice showed no additive effects from the deletion of both proteins (Fig. 1c) , and both mutations caused significantly lower fat pad weights than in WT mice (Supplementary Fig. 1b) , indicating that the mutations protect mice from DIO by a similar mechanism.
Compared with HFD-fed WT mice, HFD-fed TF ∆CT mice had lower plasma concentrations of free fatty acids (FFA), fasting Tissue factor-protease-activated receptor 2 signaling promotes diet-induced obesity and adipose inf lammation Tissue factor, the initiator of the coagulation cascade, mediates coagulation factor VIIa-dependent activation of proteaseactivated receptor 2 (PAR2). Here we delineate a role for this signaling pathway in obesity and its complications. Mice lacking PAR2 (F2rl1) or the cytoplasmic domain of tissue factor were protected from weight gain and insulin resistance induced by a high-fat diet. In hematopoietic cells, genetic ablation of tissue factor-PAR2 signaling reduced adipose tissue macrophage inflammation, and specific pharmacological inhibition of macrophage tissue factor signaling rapidly ameliorated insulin resistance. In contrast, nonhematopoietic cell tissue factor-VIIa-PAR2 signaling specifically promoted obesity. Mechanistically, adipocyte tissue factor cytoplasmic domain-dependent VIIa signaling suppressed Akt phosphorylation with concordant adverse transcriptional changes of key regulators of obesity and metabolism. Pharmacological blockade of adipocyte tissue factor in vivo reversed these effects of tissue factor-VIIa signaling and rapidly increased energy expenditure. Thus, inhibition of tissue factor signaling is a potential therapeutic avenue for improving impaired metabolism and insulin resistance in obesity.
insulin and glucose, and they also showed better insulin sensitivity and glucose tolerance ( Fig. 1d and Supplementary Fig. 2a,b) . Pronounced insulin-induced phosphorylation of Akt in adipose tissue confirmed greater insulin sensitivity of HFD-fed TF ∆CT mice compared with nonresponsive WT controls (Fig. 1d) . Similarly, F2rl1 −/− and TF ∆CT ; F2rl1 −/− mice had lower plasma FFA, fasting insulin and glucose concentrations and better glucose homeostasis relative to WT mice ( Fig. 1e and Supplementary Fig. 2c,d) . Thus, loss of the tissue factor cytoplasmic domain or PAR2 signaling produced a similar and nonadditive decrease in obesity and insulin resistance.
Chronic inflammation specifically in VAD is linked to the presence of proinflammatory adipose tissue F4/80 + CD11b + CD11c + macrophages 24 . Depletion of CD11c + cells shifts the balance to M2-like polarized F4/80 + CD11b + CD11c − macrophages that highly express the anti-inflammatory cytokine interleukin-10 (IL-10), increasing insulin sensitivity 25 . CD11b + CD11c + proinflammatory macrophages aggregate around apoptotic adipocytes to form 'crownlike-structures' (CLSs) 26 . TF ∆CT and F2rl1 −/− mice had fewer CLSs than WT mice (Fig. 1f) . FACS analysis of adipose stromal vascular fraction (SVF) cells of HFD-fed WT, TF ∆CT , F2rl1 −/− and TF ∆CT ; F2rl1 −/− mice showed that, compared with the WT mice, the obesity-protected strains had fewer CD11b + CD11c + macrophages in the inflammation-prone VAD (Fig. 1g) , but not in the subcutaneous adipose (SAD); therefore, we excluded the possibility of a general defect in macrophage recruitment. Fewer VAD macrophages probably reflected decreased obesity in the protected strains.
Tissue factor and PAR2 promote macrophage inflammation Tissue factor is induced in monocytes by the nuclear factor-κB and JNK signaling pathways 27 , which are crucial for the development of proinflammatory adipose tissue macrophages 24 . Tissue factor was expressed by CD11b + F4/80 + macrophages specifically in the inflammation-prone VAD and more highly in CD11b + CD11c + than in CD11b + CD11c − adipose tissue macrophages (Fig. 2a) . To determine the contributions of macrophage tissue factor-PAR2 signaling to adipose inflammation, we reconstituted lethally irradiated WT mice with bone marrow from TF ∆CT or F2rl1 −/− mice. After 6 weeks of engraftment, we fed mice a HFD for 16-19 weeks. Deletion of the tissue factor cytoplasmic domain or PAR2 in the hematopoietic compartment did not impair HFD-induced weight gain (Fig. 2b) , suggesting that tissue factor-PAR2 signaling in nonhematopoietic cells promoted obesity.
Donor bone marrow-derived cells accounted for >90% of the VAD macrophages (Fig. 2c) , and tissue factor expression in VAD CD11b + CD11c + adipose tissue macrophages was indistinguishable between mice reconstituted with knockout or WT bone marrow (Supplementary Fig. 3 ). However, TF ∆CT and F2rl1 −/− bone marrow chimeras had fewer VAD CD11b + CD11c + macrophages, but they had no appreciable changes in CD11b + CD11c − macrophages or CD4 + or CD8 + T cell numbers compared to WT control chimeras (Fig. 2d) . Despite the normal HFD-induced weight gain, chimeras deficient in hematopoietic tissue factor-PAR2 signaling had lower basal blood glucose concentrations and greater glucose tolerance and insulin sensitivity relative to WT controls ( Fig. 2c and Supplementary Fig. 4 ). Adipose tissues of these chimeric mice had lower mRNA levels of the proinflammatory cytokine IL-6 and higher mRNA levels of the antiinflammatory cytokine IL-10 compared with WT mice (Fig. 2e) .
Tissue factor regulates reverse endothelial transmigration of monocytes, contributing to dendritic cell maturation 28 , and tissue factor cytoplasmic domain deletion may cause reduced CD11b + CD11c + macrophage recruitment. However, tissue factor cytoplasmic domain signaling also regulates activation of myeloid cells 21, 29 and, in microglia, PAR2 triggers induction of tumor necrosis factor-α (TNF-α) and IL-6, whereas PAR2 deficiency leads to IL-10 upregulation 30 . In an independent experiment, cytokine mRNA expression in isolated CD11b + macrophages showed lower IL-6 and greater IL-10 expression in tissue factor-PAR2 signaling-deficient macrophages compared with WT macrophages (Fig. 2e) . Thus, hematopoietic tissue factor-PAR2 signaling has no role in the development of obesity, but promotes HFD-induced adipose tissue macrophage inflammation and insulin resistance.
Macrophage inflammation also contributes to hepatic steatosis 5, 31 . Through histological and biochemical analysis, we found less hepatic steatosis in the chimeras with a bone marrow deficient in tissue factor-PAR2 signaling compared with WT bone marrow transplantation controls (Fig. 2f) . However, skeletal muscle triglyceride concentrations were modestly higher than in WT chimeras (Fig. 2f,g ), consistent with other models in which lower myeloid cell inflammation is associated with lower steatosis, modestly higher muscle triglyceride concentrations and greater insulin sensitivity 32 . Accumulation of triglycerides in muscle can increase insulin sensitivity by sequestering reactive lipid metabolites such as ceramide that cause insulin resistance 33, 34 . Thus, increase in adipose, hepatic and muscle insulin sensitivity probably contributed to better glucose homeostasis in inflammation-protected TF ∆CT or F2rl1 −/− bone marrow chimeric mice.
Inhibition of tissue factor increases insulin sensitivity TF ∆CT and F2rl1 −/− adipose tissue macrophages were lower in numbers and indistinguishable from WT in the expression of CD11b and CD11c surface markers, but it remained unproven that tissue factor-PAR2 signaling directly sustained their proinflammatory phenotype. We used knock-in mice carrying human tissue factor under control of the endogenous tissue factor promoter (TFKI mice) 35 to generate bone marrow chimeras in which hematopoietic cells were humanized for tissue factor. On a HFD, these chimeric mice developed obesity and insulin resistance indistinguishable from WT bone marrow controls (Supplementary Fig. 5a,b) . In these chimeric mice, human tissue factor was expressed only in bone marrow-derived myeloid cells, allowing us to selectively block macrophage tissue factor with the species-selective monoclonal antibody 10H10 to human tissue factor that inhibits tissue factor-VIIa-PAR2 signaling, but not coagulation 21, 23 .
A single dose of monoclonal antibody 10H10 within 24 h led to lower basal blood glucose (214 ± 15 versus 245 ± 18 mg dl −1 ; P < 0.05) and better glucose homeostasis in the TFKI bone marrow chimeras relative to chimeric mice treated with isotype-matched control antibody or WT bone marrow chimera controls receiving 10H10 (Fig. 3a) . The response of both controls was indistinguishable, and the data were combined to show a single control group. Specific antibody treatment led to lower mRNA levels of proinflammatory cytokines TNF-α and IL-6 and higher mRNA levels of the anti-inflammatory IL-10 in VAD CD11b + macrophages compared with controls, but PAI-1 mRNA levels were similar to controls, demonstrating specificity (Fig. 3b) . Notably, treatment of obese bone marrow TFKI mice with antibody to human tissue factor did not appreciably reduce VAD CD11b + CD11c + macrophage counts relative to controls (Fig. 3b) , excluding the possibility that the antibody to tissue factor caused macrophage depletion. Because bone marrow transplantation replaces myeloid cells in the liver 31, 36 , tissue factor blockade probably also reduced hepatic inflammation to increase overall insulin sensitivity.
In an independent approach, we acutely blocked tissue factor in obese WT mice with monoclonal antibody 21E10, which inhibits binding of VIIa to mouse tissue factor. This treatment also increased glucose tolerance within 24 h (Fig. 3c) and was specific, as this antibody specific for mouse tissue factor did not further increase insulin sensitivity of insulin-sensitive HFD TF ∆CT mice relative to control antibody (Supplementary Fig. 5c ). As we observed with selective tissue factor blockade of myeloid cells, obese WT mice treated with antibody 21E10 had lower VAD mRNA levels of TNF-α and IL-6, higher IL-10 mRNA levels and similar counts of CD11b + CD11c + macrophages relative to those treated with control antibody (Fig. 3d) . Analysis of isolated adipose CD11b + macrophages (Fig. 3e) confirmed these cytokine changes (Fig. 3e) . However, total blockade of tissue For a,c,d, *P < 0.05, **P < 0.01, ***P < 0.001 for WT versus knockout bone marrow chimeras. (e) Body weights, food intake, activity and oxygen consumption, CO 2 output and RER in DIO mice after treatment with the anti-mouse tissue factor antibody 21E10 (n = 5, mean ± s.d.). *P < 0.05 for control versus 21E10-treated mice.
factor reduced mRNA levels of PAI-1 in VAD but not in isolated macrophages, indicating that tissue factor-PAR2 signaling also occurred in a nonhematopoietic cell type, presumably the adipocyte. Thus, inhibition of tissue factor signaling rapidly changes adipose tissue macrophage phenotypes to increase insulin sensitivity in obesity.
Nonhematopoietic tissue factor and PAR2 promote obesity To address roles of nonhematopoietic tissue factor-PAR2 signaling in the development of obesity, we transplanted WT bone marrow into TF ∆CT and F2rl1 −/− mice. Compared with WT recipient controls, mice with a stromal compartment deficient in tissue factor-PAR2 signaling showed less HFD-induced weight gain (Fig. 4a) . Histological and biochemical analysis of mice fed a HFD for 18 weeks showed fewer CLSs in VAD and lower liver weight, hepatic steatosis and muscle triglyceride accumulation in chimeric TF ∆CT and F2rl1 −/− mice compared with WT controls (Fig. 4b,c) . The metabolic improvements were reflected in lower FFA and blood glucose in chimeric mutant mice compared with WT bone marrow chimeras (Fig. 4c) . FACS analysis of VAD SVF cells confirmed fewer CD11b + CD11c + macrophages than in WT chimeras, indicating that a decrease in obesity indirectly caused less recruitment of macrophages with normal tissue factor-PAR2 signaling (Fig. 4c) .
As WT bone marrow chimeric TF ∆CT and F2rl1 −/− mice were hyperphagic and more active than WT recipient controls, we excluded the possibility that the lower weight gain was caused by decreased food intake (Fig. 4d) . Both TF ∆CT mice with WT bone marrow (Fig. 4d) and whole-body TF ∆CT mice (Supplementary Fig. 6a ) showed greater oxygen consumption and CO 2 output in indirect calorimetry with similar or slightly lower respiratory exchange ratios (RERs) relative to WT controls, suggesting that increased metabolism without impairments in fat metabolism contributed to the lower body weight in TF ∆CT mice. To eliminate differences in body weight and activity as variables, we further blocked tissue factor acutely in obese WT mice during metabolic evaluation. Blocking tissue factor with the antibody 21E10 in weight-matched DIO mice caused no changes in activity or food intake relative to control antibody but led to significantly greater oxygen consumption and CO 2 output and modestly lower RER, indicating increased metabolism and fatty acid oxidation (Fig. 4e) . Because tissue factor is not detectable in skeletal muscle cells or hepatocytes by (d) Gene expression in adipocytes isolated from VAD of DIO WT or TFKI bone marrow chimeric mice treated overnight with antibody 21E10 to mouse tissue factor or antibody 10H10 to human tissue factor; n = 8-14, mean ± s.d. *P < 0.05, **P < 0.01 for control versus specific antibody-treated mice.
(e) Insulin tolerance tests of obese TFKI bone marrow chimeras 24 h after receiving antibody 21E10 compared to obese TFKI bone marrow chimeras receiving control IgG. (f) Gene expression in SVF fraction cells isolated from VAD of DIO TFKI bone marrow chimeric mice treated with murine TFspecific antibody 21E10. For e,f, n = 8, mean ± s.d. *P < 0.05, **P < 0.01 for control versus specific antibody-treated mice.
in situ hybridization 37, 38 , the increased energy expenditure and metabolism after anti-tissue factor therapy or genetic tissue factor cytoplasmic domain deletion in the stromal compartment probably originated from alteration of tissue factor signaling in the adipocyte. Despite greater food intake and activity, oxygen consumption and CO 2 output were not significantly increased in WT bone marrow chimeric F2rl1 −/− mice relative to WT controls (Fig. 4d) . Similarly, compared with WT controls, whole-body F2rl1 −/− mice did not show increased metabolism in an experiment where activity or food intake were unchanged relative to WT controls (Supplementary Fig. 6b) . However, oxygen consumption (VO 2 ) and CO 2 output were significantly greater for F2rl1 −/− groups when normalized for body weight ( Supplementary  Fig. 6c,d) . RER was modestly but significantly greater in F2rl1 −/− relative to WT mice, indicating impaired fatty acid oxidation, consistent with the proposed role of adipocyte PAR2 G protein-coupled signaling in activating AMPK 12 . However, similar to TF ∆CT chimeric mice, WT bone marrow F2rl1 −/− mice had lower triglyceride levels in liver and skeletal muscle relative to WT bone marrow chimera controls (Fig. 4b,c) , indicating that deletion of tissue factor or PAR2 signaling in adipocytes has common beneficial effects on other insulin-sensitive tissues.
Adipocyte tissue factor-VIIa signaling regulates obesity Considering that PAR2 β-arrestin signaling suppresses PI-3 kinase activation and that insulin-induced Akt phosphorylation was not inhibited in obese TF ∆CT mice (Fig. 1) , we investigated whether adipocyte Akt activation is directly regulated by tissue factor-VIIa-PAR2 signaling. In in vitro-differentiated adipocytes from WT mice, but not from TF ∆CT mice, VIIa suppressed basal Akt phosphorylation in a tissue factor-dependent manner (Fig. 5a) . Insulin-induced Akt phosphorylation was similarly inhibited in VIIa-treated WT, but not in TF ∆CT adipocytes (Fig. 5b) . Notably, Akt activation was preserved in insulin-treated WT adipocytes when VIIa binding to tissue factor was blocked with antibody 21E10 to mouse tissue factor. Thus, tissue factor directly regulates adipocyte Akt activation.
Adipocyte tissue factor-VIIa signaling regulated Akt-dependent target genes implicated in obesity and insulin resistance (Fig. 5c) . Stimulation of 3T3-L1 adipocytes for 3 h with VIIa, but not thrombin (data not shown), increased in a tissue factor-dependent manner mRNA expression of the obesity promoter PAI-1, which is negatively regulated by Akt in adipocytes 39 . Akt activation supports adiponectin expression in adipocytes 40 . VIIa stimulation reduced mRNA levels of this adipokine, which upregulates glucose and lipid metabolism broadly in other insulin-sensitive tissue and thereby prevents obesity [41] [42] [43] . Adiponectin activates AMPK and, consistently, VIIa suppressed the mRNA expression of targets downstream of AMPK, including uncoupling protein-2 (UCP-2) and peroxisome proliferatoractivated receptor-α (PPAR-α), which are involved in energy expenditure 44 and fatty acid oxidation 45 , respectively. Suppression of AMPK may in part also be directly mediated by β-arrestin downstream of tissue factor-VIIa-PAR2 signaling 12 . In addition, tissue factor-VIIa signaling increased adipocyte mRNA synthesis of TNF-α, a key inflammatory mediator that promotes obesity and insulin resistance 46 . Thus, adipocyte tissue factor-VIIa signaling regulates crucial effectors that contribute to the development of DIO.
To demonstrate that adipocyte tissue factor signaling in vivo regulates the same target genes, as seen in cultured cells, we isolated adipocytes from the VAD of WT mice 24 h after treatment with antibody 21E10 to mouse tissue factor. Blockade of tissue factor reduced mRNA levels of PAI-1 and TNF-α and increased mRNA expression of adiponectin, UCP-2 and PPAR-α (Fig. 5d) , demonstrating a reversal of tissue factor-VIIa signaling effects observed in cultured adipocytes. These changes were directly caused by tissue factor adipocyte signaling, because the mouse tissue factor-specific antibody 21E10 (Supplementary Fig. 7 ) caused the same changes in treated bone marrow chimeric mice with human tissue factor in hematopoietic cells (Fig. 5d) . Conversely, blocking human tissue factor signaling in the hematopoietic compartment of the chimeric mice with antibody 10H10 had no effect on the adipocyte expression of the same target genes relative to control. These data establish direct and independent regulatory roles for adipocyte tissue factor signaling in the expression of key mediators of weight gain 42, [47] [48] [49] .
Tissue factor is expressed by neither skeletal muscle nor hepatocytes 37, 38 , and restrictions of the blood-brain barrier would exclude central effects of acutely administered antibody. Blocking nonhematopoietic tissue factor in the human-mouse tissue factor chimeric mice ameliorated insulin resistance within 24 h (Fig. 5e) . To determine whether the increased insulin sensitivity was independent of changes in adipose inflammation, we assayed inflammatory cytokines in SVF cells, which contain the macrophage populations. As we expected, blocking hematopoietic tissue factor signaling with the human tissue factor-specific antibody 10H10 increased IL-10 and suppressed IL-6 and TNF-α mRNA levels in SVF cells from these chimeric mice (Fig. 5f) . Blocking tissue factor specifically in nonhematopoietic cells with the mouse tissue factorspecific antibody 21E10 had no effect on IL-10 mRNA expression (Fig. 5f) . Thus, macrophage tissue factor signaling specifically regulates IL-10 expression independent of potential cross-talk from adipocytes. Conversely, neither antibody changed PAI-1 mRNA expression in SVF cells, confirming adipocyte-specific regulation of PAI-1 by tissue factor signaling (Fig. 5f) . However, inhibition of nonhematopoietic tissue factor reduced mRNA levels of TNF-α and IL-6 in SVF cells. These data indicate that increased insulin sensitivity in response to tissue factor blockade on adipocytes may, in part, involve reduced adipose tissue inflammation. Figure 6 Schematic overview of the contributions of macrophage and adipocyte tissue factor-PAR2 signaling to insulin resistance and obesity. PAR2 via β-arrestin inhibits phosphoinositide 3-kinase and Akt phosphorylation. In adipocytes, tissue factor cytoplasmic domaindependent tissue factor-VIIa signaling inhibits both basal and insulinmediated activation of Akt. Suppression of Akt activity contributes to insulin resistance and decreases adiponectin synthesis by adipocytes. Reduced adiponectin systemically blunts insulin signaling and inhibits AMPK and PPAR-α pathways of energy expenditure and β-oxidation, causing obesity. In adipose tissue macrophages, tissue factor-PAR2 signaling sustains M1 macrophage polarization, leading to the increased production of inflammatory mediators (TNF-α, IL-6) and reduced levels of the anti-inflammatory cytokine IL-10, contributing to insulin resistance.
DISCUSSION
established proinflammatory effects of tissue factor cytoplasmic domain and PAR2 signaling in myeloid cells 21, 29 , genetic loss of this signaling pathway attenuated adipose macrophage inflammation and increased insulin sensitivity. Notably, acute blockade of macrophage tissue factor-VIIa signaling produced a rapid phenotypic switch of adipose tissue proinflammatory macrophages, leading to downregulation of TNF-α and IL-6 and upregulation of the anti-inflammatory cytokine IL-10 (Fig. 6) . These changes in macrophage phenotype are directly linked to insulin sensitivity, as neutralization of TNF-α enhances insulin signaling in the adipose tissue and muscle 46, 50, 51 , reduction of adipose IL-6 decreases hepatic insulin resistance by downregulation of SOCS3 (ref. 52) , and IL-10 protects against TNF-α-mediated insulin resistance in adipocytes 53 . Notably, selective blockade of macrophage tissue factor signaling in chimeric mice was sufficient to reverse insulin resistance independent of changes in adipocyte-derived metabolic regulators. The phenotypic switch of adipose tissue macrophages in these mice was reminiscent of macrophage-mediated anti-inflammatory and insulin-sensitizing effects after activation of GPR120 by omega-3 fatty acid 2 .
Although our data show that tissue factor signaling directly regulates adipose tissue macrophage inflammation, tissue factor in the nonhematopoietic compartment induced adipocyte expression of PAI-1 and indirectly supported macrophage production of TNF-α and IL-6, but not of IL-10. We observed the reduction of macrophage inflammatory cytokine abundance in mice treated with the antibody 21E10, which reversed PAI-1 expression in adipocytes but also directly blocked coagulation. This suggests that adipocyte tissue factor-induced coagulation in conjunction with PAI-1-mediated suppression of fibrinolysis could increase local fibrin deposition required for the proinflammatory phenotype of adipose tissue macrophages. Indeed, integrin α M β 2 interaction with fibrin is crucial for macrophage activation and inflammatory cytokine production [54] [55] [56] . Thus, the mechanistic coupling of fibrin generation and innate immune cell-driven inflammation may cause adipose tissue inflammation and metabolic syndrome.
The absence of tissue factor cytoplasmic domain signaling in nonhematopoietic cells produced an obesity-resistant phenotype. Acute disruption of the ligand interaction between tissue factor and VIIa rapidly improved metabolic control independent of changes in body weight, food intake or locomotor activity. Mechanistically, adipocyte tissue factor-VIIa signaling initiates tissue factor cytoplasmic domain-dependent suppression of basal and insulin-mediated Akt phosphorylation and alters the expression of Akt-regulated target genes causally linked to weight gain in DIO 14, 42, 45, 48, 49 . Of these, adiponectin, an adipokine produced exclusively by adipocytes, regulates glucose uptake, AMPK activation and fatty acid oxidation and has additional central effects on body weight reduction 42 . Thus, tissue factor-Vlla-mediated suppression of adipocyte adiponectin broadly influences insulin-responsive target tissues, reduces energy expenditure and thereby contributes to an obese phenotype (Fig. 6) . Notably, these experiments demonstrate synergistic and independent roles for adipocyte and immune cell tissue factor signaling in the metabolic impairments of obesity.
Increasing insulin sensitivity without the side effects of weight gain, as has been observed for PPAR-γ agonists, is a major challenge in therapies for diabetes. A blocking antibody to tissue factor with rapid signaling and minimal risks of bleeding complications may provide a new approach to targeting the metabolic complications of obesity, and could induce weight loss through independent effects on the regulation of energy expenditure by adipocytes.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
